Comparative bioavailability evaluation of two cyclosporine oral formulations in healthy Mexican volunteers

Archives of Medical Research

Volumn 30, Issue 4, 1999, Pages 315-319

  González Llaven, José ^a   Palma Aguirre, José Antonio ^b   García Arreola, Rosa ^a   Brizuela, Verónica ^a   Nava Rangel, Joel ^b   Morán Lira, Silvia ^a   Vela Ojeda, Jorge ^a   Castañeda Hernández, Gilberto ^c   Flores Murrieta, Francisco Javier ^c  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Bioavailability; Cyclosporine; Healthy volunteers; Pharmacokinetics

Indexed keywords

CYCLOSPORIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; HUMAN; MALE; MICROEMULSION; RANDOMIZED CONTROLLED TRIAL;

EID: 0033167320     PISSN: 01880128     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0188-0128(99)00034-2     Document Type: Article

References (27)

1. Cyclosporine in cadaveric renal transplantation. one year follow-up of multicentre trial Lancet. 2:1983;986.
2. Tan K.K., Trull A.K., Uttridge J.A. Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther. 57:1995;425.
3. Ptachcinski R.J., Venkataramanan R., Rosenthal J.T.et al. Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther. 38:1985;296.
4. Drewe J., Beglinger C., Kissel T. The absorption site of cyclosporine in the human gastrointestinal tract. Br J Clin Pharmacol. 33:1992;39.
5. Tan K.K., Trull A.K., Uttridge J.A.et al. Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in renal transplant recipients. Transplant Proc. 26:1994;2955.
6. Gupta S.K., Manfro R.C., Tomlanovich S.J., Gambertoglio J.G., Garovoy M.R., Benet L.Z. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects after oral and intravenous administration. J Clin Pharmacol. 30:1990;643.
7. Zhi J., Rakhit A., Patel I.H. Effects of dietary fat on drug absorption. Clin Pharmacol Ther. 58:1995;487.
8. Mehta M., Venkataramanan R., Buckart G.J. Effects of bile on cyclosporine absorption in liver transplant patients. Br J Clin Pharmacol. 25:1984;579.
9. Vonderscher J., Meinzer R. Rationale for the development of Sandimmun Neoral. Transplant Proc. 26:1994;2925.
10. Lindholm A., Kahan B.D. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 54:1993;205.
11. Friman S., Backman L. A new microemulsion formulation of cyclosporine. Clin Pharmacokinet. 30:1996;181.
12. Palma-Aguirre J.A., Gónzalez-Llaven J., Flores-Murrieta F.J., Castañeda-Hernández G. Bioavailability of oral cyclosporine in healthy Mexican volunteers. evidence for interethnic variability J Clin Pharmacol. 37:1997;630.
13. Quesniaux V., Tees R., Schreier M.H.et al. Monoclonal antibodies to cyclosporine. Prog Allergy. 38:1986;108.
14. Rowland M., Tozer T.N. Clinical pharmacokinetics. concepts and applications 2nd ed:1989;Lea and Febiger, Philadelphia.
15. Schuirmann D.J. A comparison of the two one-sided test procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 15:1987;657.
16. Drewe J., Meier R., Vonderscher J.et al. Enhancement of the absorption of cyclosporine in man. Br J Clin Pharmacol. 34:1992;60.
17. Mueller E.A., Kovarik J.M., van Bree J.B.et al. Improved dose linearity of cyclosporine pharmacokinetics from microemulsion formation. Pharm Res. 11:1994;301.
18. Mueller E.A., Kovarik J.M., van Bree J.B.et al. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res. 11:1994;151.
19. Kovarik J.M., Mueller E.A., Johnston A.et al. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy. 13:1993;613.
20. Kovarik J.M., Mueller E.A., van Bree J.B.et al. Reduced inter- and intra-individual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci. 83:1994;444.
21. Mueller E.A., Kovarik J.M., Kutz K. Minor influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine. Transplant. 26:1994;2957.
22. Kovarik J.M., Vaernillet L., Mueller E.A.et al. Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemulsion formulation. Ther Drug Monit. 16:1994;519.
23. ®). Drugs. 50:1995;924.
24. Taesch S., Niese D. Safety and tolerability of a new oral formulation of cyclosporine A Sandimmun neoral in renal transplant patients. Transplant Int. 7(Suppl 1):1994;263.
25. Neumayer H.H., Farber L., Haller P.et al. Conversion from Sandimmun to Sandimmun neoral in patients with stable renal allografts. results after 1 month Transplant. 26:1994;2944.
26. Wahlberg J., Wilczek H., Fauchald P.et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplant. 60:1995;648.
27. Castañeda-Hernández G., Palma-Aguirre J.A., Montoya-Cabrera M.A., Flores-Murrieta F.J. Interethnic variability in nifedipine disposition. reduced systemic plasma clearance in Mexican subjects Br J Clin Pharmacol. 41:1996;433.